BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioLife Solutions, Inc. (NasdaqCM: BLFS) to Repligen Corporation (NasdaqGS: RGEN). Under the terms of the proposed transaction, shareholders of BioLife will receive $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife that they own. KSF is seeking to determine whe.

Business Wire • Jul 24, 2026

BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal

BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 billion by the life sciences corporation Repligen.

GeekWire • Jul 23, 2026

Repligen to Expand Cell Therapy Capabilities With BioLife Buyout

RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.

Zacks Investment Research • Jul 23, 2026

Repligen to buy cell therapy maker BioLife in $1.5 billion deal

Repligen Corp said on ​Wednesday it would buy ‌BioLife Solutions in a cash-and-stock deal valued at about $1.5 ​billion, to expand the drugmaking ​equipment provider's presence in ⁠the fast-growing cell ​therapy market.

Reuters • Jul 22, 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS)

NEW YORK, July 22, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating BioLife Solutions, Inc. (NASDAQ: BLFS ) related to its sale to Repligen Corporation.

PRNewsWire • Jul 22, 2026

Shareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, July 22, 2026 /PRNewswire/ -- Ademi LLP is investigating BioLife (NASDAQ: BLFS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Repligen. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

PRNewsWire • Jul 22, 2026

BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share in cash and 0.1442 shares of Repligen common stock. Halper Sadeh encourages BioLife shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns w.

Business Wire • Jul 22, 2026

Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition

Life sciences company Repligen Corporation (NASDAQ:RGEN) on Wednesday agreed to acquire cell processing developer BioLife Solutions Inc. (NASDAQ:BLFS) for an enterprise value of approximately $1.5 billion.

Benzinga • Jul 22, 2026

Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach

Repligen NASDAQ: RGEN said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen's exposure to one of the faster-growing areas of bioprocessing.

MarketBeat • Jul 22, 2026

Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media

Fast-tracks Repligen's leadership and customer solution offering in high-growth cell therapy market by adding BioLife's differentiated, high-margin recurring revenue business

GlobeNewsWire • Jul 22, 2026